Monte Rosa Therapeutics, Inc. Common Stock
$12.65
-$0.34 (-2.62%)
$12.59Day Range$13.01
Key Statistics
Market Cap
$1.08B
Shares Outstanding
85.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Jun 24, 2021
Round Lot
100
Locale
US
Trading Data
Day Open
$12.94
Day High
$13.01
Day Low
$12.59
Volume
1.50M
VWAP
$12.71
Prev Close
$12.99
Transactions
--
Acc. Volume
--
About Monte Rosa Therapeutics, Inc. Common Stock
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 2836173 employees321 HARRISON AVENUE, BOSTON, MA, 02118617-949-2643IPO Jun 24, 2021US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001826457
- Composite FIGI
- BBG00X2VGZQ3
- Share Class FIGI
- BBG00X2VGZR2
- Ticker Root
- GLUE
- SIC Code
- 2836
About Monte Rosa Therapeutics, Inc. Common Stock (GLUE) Stock
Monte Rosa Therapeutics, Inc. Common Stock (GLUE) closed the 2026-09-16 session at $12.65, down 2.62% versus the previous close (-0.34). The stock opened at $12.94 and traded between $12.59 and $13.01 during that session. Session trading volume was 1.5M shares. The volume-weighted average price (VWAP) is $12.71.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Monte Rosa Therapeutics, Inc. Common Stock has a market capitalization of $1.08 billion. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. GLUE is listed on the XNAS exchange. The company employs approximately 173 people. Monte Rosa Therapeutics, Inc. Common Stock is headquartered in BOSTON, MA. The recorded listing date is 2021-06-24.
On this page you can find market GLUE stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.